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Abstract. In 2015, there were an estimated 415 million people diagnosed with DM in the world. DM 
disability and mortality are directly associated with late vascular complications (cardiovascular disease, 
retinopathy, renal failure, encephalopathy, impaired peripheral blood circulation, and others). Accumulation of 
advanced glycation end products (AGEs) in tissues is considered as a main driver of these complications. Non-
enzymatic glycation of proteins (Maillard reaction) is the way of AGEs formation.  
 
We have proposed a synthetic scheme towards promising class of azoloazine heterocycles (1) and proved 
antidiabetic potential of these compounds by computational methods and experiments in vitro. It was shown that 
azoloazines (1) demonstrated higher antiglycation activity than reference compound, aminoguanidine, and have 
some potential as dipeptidylpeptidase-4 inhibitors. By given results this class of heterocycles can be considered as 
candidate for extended studies to develop drugs against complications of T2DM [1,2]. 
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